SAR studies: Designing potent and selective LXR agonists

Lead screening at Merck identified a potent, dual LXR/PPAR agonist. SAR optimization developed a series of LXR specific heterocyclic agonists having excellent LXR affinity, good in vivo, potency and high selectivity versus other nuclear hormone receptors.